Sandbox Reserved 1791
From Proteopedia
(Difference between revisions)
Line 32: | Line 32: | ||
|} | |} | ||
== Specific Residues and Interactions== | == Specific Residues and Interactions== | ||
- | On the concave surface of the LRRD two <scene name='95/952719/Specific_residues/6'>lysine residues</scene> are the main contributors to the binding of the antibodies. The concave structure of the binding pocket allows a <scene name='95/952719/Lock_and_key/8'>tight interaction</scene> with antibodies. Specifically, <scene name='95/952719/K---e_interaction/8'>LYS 58</scene> interacts with Glu 118 and <scene name='95/952719/K---d_interaction/9'>LYS 209</scene> interacts with Asp 111 on K1 and M22 antibodies to make a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction]. The interaction is not close enough to make a hydrogen bond. Instead, the interaction between the Lys residues with the Asp or Glu residues is a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction] because the distance between the residues is greater than 2Å. When in the inactive form, LYS 209 interaction is absent but LYS 58 interaction with Glu 118 is present. These salt bridge interactions are highly specific as mutation of Lys209 to Arg induced a different interaction. This new interaction | + | On the concave surface of the LRRD two <scene name='95/952719/Specific_residues/6'>lysine residues</scene> are the main contributors to the binding of the antibodies. The concave structure of the binding pocket allows a <scene name='95/952719/Lock_and_key/8'>tight interaction</scene> with antibodies. Specifically, <scene name='95/952719/K---e_interaction/8'>LYS 58</scene> interacts with Glu 118 and <scene name='95/952719/K---d_interaction/9'>LYS 209</scene> interacts with Asp 111 on K1 and M22 antibodies to make a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction]. The interaction is not close enough to make a hydrogen bond. Instead, the interaction between the Lys residues with the Asp or Glu residues is a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction] because the distance between the residues is greater than 2Å. When in the inactive form, LYS 209 interaction is absent but LYS 58 interaction with Glu 118 is present. These salt bridge interactions are highly specific as mutation of Lys209 to Arg induced a different interaction. This new interaction widens the selectivity of TSHR, allowing it to bind to other hormones like [https://my.clevelandclinic.org/health/articles/22489-human-chorionic-gonadotropin hCG] <ref name="Guillaume">Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002 Apr;16(4):722-35. doi: 10.1210/mend.16.4.0815. PMID: 11923469. [DOI: 10.1210/mend.16.4.0815 https://pubmed.ncbi.nlm.nih.gov/11923469/]</ref>. |
== Biological Relevance == | == Biological Relevance == |
Revision as of 02:58, 21 April 2023
This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795. |
To get started:
More help: Help:Editing |
Thyroid Stimulating Hormone Receptor (TSHR)
|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Faust B, Billesbolle CB, Suomivuori CM, Singh I, Zhang K, Hoppe N, Pinto AFM, Diedrich JK, Muftuoglu Y, Szkudlinski MW, Saghatelian A, Dror RO, Cheng Y, Manglik A. Autoantibody mimicry of hormone action at the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05159-1. doi:, 10.1038/s41586-022-05159-1. PMID:35940205 doi:http://dx.doi.org/10.1038/s41586-022-05159-1
- ↑ 2.0 2.1 2.2 2.3 Duan J, Xu P, Luan X, Ji Y, He X, Song N, Yuan Q, Jin Y, Cheng X, Jiang H, Zheng J, Zhang S, Jiang Y, Xu HE. Hormone- and antibody-mediated activation of the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05173-3. doi:, 10.1038/s41586-022-05173-3. PMID:35940204 doi:http://dx.doi.org/10.1038/s41586-022-05173-3
- ↑ Fokina, E.F., Shpakov, A.O. Thyroid-Stimulating Hormone Receptor: the Role in the Development of Thyroid Pathology and Its Correction. J Evol Biochem Phys 58, 1439–1454 (2022). [DOI:10.1134/S0022093022050143 https://doi.org/10.1134/S0022093022050143]
- ↑ Chen CR, McLachlan SM, Rapoport B. Thyrotropin (TSH) receptor residue E251 in the extracellular leucine-rich repeat domain is critical for linking TSH binding to receptor activation. Endocrinology. 2010 Apr;151(4):1940-7. doi: 10.1210/en.2009-1430. Epub 2010 Feb 24. PMID: 20181794; PMCID: PMC2851189. [DOI 10.1210/en.2009-1430 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851189/]
- ↑ 5.0 5.1 Goel R, Raju R, Maharudraiah J, Sameer Kumar GS, Ghosh K, Kumar A, Lakshmi TP, Sharma J, Sharma R, Balakrishnan L, Pan A, Kandasamy K, Christopher R, Krishna V, Mohan SS, Harsha HC, Mathur PP, Pandey A, Keshava Prasad TS. A Signaling Network of Thyroid-Stimulating Hormone. J Proteomics Bioinform. 2011 Oct 29;4:10.4172/jpb.1000195. PMID:24255551 doi:10.4172/jpb.1000195
- ↑ Maeda S, Koehl A, Matile H, Hu H, Hilger D, Schertler GFX, Manglik A, Skiniotis G, Dawson RJP, Kobilka BK. Development of an antibody fragment that stabilizes GPCR/G-protein complexes. Nat Commun. 2018 Sep 13;9(1):3712. doi: 10.1038/s41467-018-06002-w. PMID:30213947 doi:http://dx.doi.org/10.1038/s41467-018-06002-w
- ↑ Nunez Miguel R, Sanders J, Chirgadze DY, Furmaniak J, Rees Smith B. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions. J Mol Endocrinol. 2009 May;42(5):381-95. Epub 2009 Feb 16. PMID:19221175 doi:10.1677/JME-08-0152
- ↑ Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002 Apr;16(4):722-35. doi: 10.1210/mend.16.4.0815. PMID: 11923469. [DOI: 10.1210/mend.16.4.0815 https://pubmed.ncbi.nlm.nih.gov/11923469/]
- ↑ 9.0 9.1 Chiovato L, Magri F, Carlé A. Hypothyroidism in Context: Where We've Been and Where We're Going. Adv Ther. 2019 Sep;36(Suppl 2):47-58. doi: 10.1007/s12325-019-01080-8. Epub 2019 Sep 4. PMID: 31485975; PMCID: PMC6822815. [DOI: 10.1007/s12325-019-01080-8 https://pubmed.ncbi.nlm.nih.gov/31485975/]